Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 6.47 -0.01 (0.15%)
Day High: 6.60
Day Low:  6.30
Volume:    469,408
4:00 PM ET
Nov 17, 2017

Delayed ~20 min., by eSignal.